“Better Health & Medicine through Innovation Linkages”
|Priority||Innovation and knowledge development|
|Aim||The proposed Med-Inno-Link is expected to deal with: (1) enhancing innovation linkages among health/medical actors in the region in order to improve the performance and efficiency of the medical system; and (2) to make the sector more competitive through innovation and enhance its export capacity (pharmaceuticals, medical products and services, including rehabilitation, healthy aging, and health tourism).|
|Results|| Published rankings of top 10% individual entities - actors in health/medical, as well as life science activities in each region/country – giving them recognition as the best performers within the region/country, and providing them with some promotion in Central Europe and beyond
An inventory of innovative medical and life sciences R&D agglomerations with potential to boost the respective areas where partners are reaching excellent results
Based on these results the respective ecosystem support institutions and companies will be encouraged to help select and develop regional projects – involving regional actors from academia, companies, and clinical institutions. By pulling regional human and other resources, chances for successful innovation will be essentially increased – contributing to higher competitiveness of the respective sectors and regional actors.
Mentoring and coaching for leading teams of promising projects – helping them to develop/finalize their projects into bankable projects (sometimes pulling 2 or even more initiatives into one “Winner project” – of relevance for a bigger territory or perhaps even the whole Central European region); obviously priority will be given to projects with potential to come to the market in the shortest possible time.
Match-making and professional consultations among organisations sharing potential professional and business interests, which could benefit from closer collaboration – which could lead towards closer collaboration among associations, clusters, and other forms of business and R&D aggregations.
Evaluation of changes necessary to make regional/national innovation ecosystems perform optimally (with particular reference to the health sector) should be done at regional/national level by the respective project partner – involving all relevant actors and stakeholders.
At the closing project conference a wider selection of actors with potential impact on making the region more competitive will be invited (banks, investors, universities, medical training centres, hospitals and clinics, elderly care homes, governments, relevant professional and business associations, NGOs, etc.
|Partners involved||Slovenian Innovation Hub, Ljubljana, Slovenia
Area Science Park, Trieste, Italy
|Partners requested||Austria (particularly Steiermark, Vienna and Kaernten), and Germany (specially Bayern and Baden Wuerttemberg), and Hungary (specially Budapest), Croatia|
|Innovation||Strengthening regional innovation ecosystems active in health and medicine, joint innovation support services, identifying strategic value chains and strategic collaborations of multi-helix players in strategic RIS3 area (health and medicine) to increase leadership in CE, Eu and globally.|
|Follow up of|
|Follow up fundings|